Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05363280
PHASE2

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

Sponsor: Advenchen Pharmaceuticals, LLC.

View on ClinicalTrials.gov

Summary

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients , Non-Small Cell Lung (NSCLC) and Renal Cell Carcinoma patients who need ≥2nd line treatment .

Official title: A Phase 2 Evaluation of the Safety and Efficacy of Veonetinib (AL8326) in ≥2nd Line Small Cell Lung Cancer (SCLC), Non Small Cell Lung Cancer (NSCLC) and Renal Cell Carcinoma (RCC) Treatment

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

80

Start Date

2022-11-01

Completion Date

2028-12

Last Updated

2026-05-08

Healthy Volunteers

No

Interventions

DRUG

AL8326 40 mg

Taken AL3826 at 40mg QD orally

DRUG

AL8326 60 mg

Taken AL3826 at 60mg QD orally

DRUG

AL8326 80 mg--stopped

Taken AL3826 at 80 mg QD orally

Locations (7)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Cleveland Clinic Florida

Weston, Florida, United States

Northwestern University

Chicago, Illinois, United States

Siteman Cancer Center, Washington University

St Louis, Missouri, United States

Cleveland Clinic

Cleveland, Ohio, United States

Hospital Universitari Vall d'Hebron

Barcelona, Spain

Hospital Universitario Ramón Y Cajal

Madrid, Spain